Giant Cell Arteritis
The PBS subsidises tocilizumab for patients with giant cell arteritis.
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with tocilizumab under the National Health Act 1953, section 85 for patients with giant cell arteritis (GCA).
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing tocilizumab.
To be eligible for PBS subsidised treatment with tocilizumab patients must be treated by a rheumatologist, clinical immunologist or neurologist experienced in the management of GCA. The treatment mustn’t exceed 52 weeks in total.
Apply for initial authority approval to prescribe PBS subsidised tocilizumab to treat active GCA in writing and either:
All applications must include the completed:
- authority prescription form or forms
- giant cell arteritis initial PBS authority application form
- relevant attachments.
To apply for continuing PBS subsidised tocilizumab to treat GCA, call the PBS Complex Drugs Programs enquiry line.
Call the PBS Complex Drugs Programs enquiry line for more information.
Page last updated: 20 January 2020
This information was printed 6 July 2020 from https://www.servicesaustralia.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/giant-cell-arteritis. It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.servicesaustralia.gov.au/individuals/site-notices when using this material.